OVIDOvid Therapeutics Inc.
Pharmaceutical Preparations
- Revenue
- $7M
- 1181% YoY
- Operating margin
- -585.2%
- 95% YoY
- EBITDA
- −$42M
- 31% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired66% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $208M | $2M | $392K | $566K | $7M | 1181% |
| Operating income | $124M | −$56M | −$59M | −$62M | −$42M | 31% |
| Net income | $123M | −$54M | −$52M | −$26M | −$17M | 34% |
| Operating cash flow | $119M | −$55M | −$46M | −$56M | −$38M | 31% |
| Capex | $184K | $1M | $40K | $71K | $0 | 100% |
| Stock-based comp | $5M | $7M | $7M | $6M | $5M | 23% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $4M | 88 | — |
| FY2024 | $3M | $36K | 29 | — |
| FY2023 | $2M | $3M | 100 | — |